The anti-neprilysin market is an emerging therapeutic area for cardiovascular diseases. Neprilysin inhibitors work by degrading endogenous vasoactive peptides that are involved in cardiovascular functions. The approval of the first-in-class drug Entresto for heart failure treatment opened up opportunities for other players to enter this space. The anti-neprilysin drugs offer an alternative treatment option for various cardiovascular conditions.
The global anti-neprilysin market is estimated to be valued at US$ 1382.2 Mn in 2024 and is expected to exhibit a CAGR of 4.6% over the forecast period 2024 to 2031.
Cardiovascular diseases such as heart failure, myocardial infarction and hypertension are highly prevalent worldwide. The unmet needs in heart failure management are driving the demand for novel drugs such as neprilysin inhibitors.
Key Takeaways
Key players operating in the anti-neprilysin market are BIOPROJET, Novartis AG, Pharmaleads SA, Theravance Biopharm, Cipla Inc, and Oceanic Pharmachem Pvt. Ltd.
The rising geriatric population susceptible to heart diseases and limited treatment options present significant growth opportunities.
Global expansion of the anti-neprilysin market players into developing regions such as Asia Pacific and Latin America will help capture untapped markets.
Market Drivers
The key driver for the Anti-Neprilysin Market Growth is the rising prevalence of cardiovascular diseases globally. Cardiovascular conditions such as heart failure, myocardial infarction and hypertension affect millions worldwide and remain a leading cause of mortality. The neprilysin inhibitors target these large disease indications by novel mechanisms of action different from existing heart failure drugs.
Get more insights on Anti-Neprilysin Market
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)